The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other antipsychotics.

The first new kind of treatment for schizophrenia patients in decades is arriving. The U.S. Food and Drug Administration approved the drug on Thursday, greenlighting the first of a new class of treatments that could help stabilize patients’ symptoms without the uncomfortable side effects that accompany existing antipsychotics.

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical company.